Prøve GULL - Gratis

“Our ambition requires us to take long-term view, investing in scale and building unmatched capabilities”

BioSpectrum Asia

|

January 2023

The novel trend in single-cell analysis is revolutionising biological research, unravelling underlying genetic credentials while creating new therapeutic approaches and personalised treatments.

- Hithaishi C Bhaskar

“Our ambition requires us to take long-term view, investing in scale and building unmatched capabilities”

For it to become more feasible, powerful, reliable tools can fuel scientific discoveries and drive exponential progress to refine genetic analysis for developing better treatment regimens. A study by Grand View Research reveals that the global single-cell analysis market size was valued at 3.28 billion in 2021 and is expected to expand at a compound annual growth rate CAGR) of 18.5 per cent from 2022 to 2030. Aware of the burgoing growth of single-cell-analysis market, Dr Ben Hindson, President Co-Founder of 10x Genomics explains how innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more areas using innovative diagnosis and therapy techniques.

What are the drivers and trends shaping the single-cell-analysis market? How do you Identify growth segments for investment and expansion?

More and more, we see that single cell methods are becoming the standard for a growing fraction of life science research, an essential element of many new grant applications and are increasingly becoming a requirement for publication.

Our goal at 10x Genomics is to make single cell analysis accessible to every biology lab in the world to make it the standard for most biological research.

Since the initial launch of our Single Cell Gene Expression solution, we have released many new capabilities and versions of our products focused on expanding the range of applications on the platform, including immune-profiling, epigenetics, proteins and multi-omics.

We have expanded the fundamental capabilities of the platform, highlighted by the release of the Chromium X instrument, which has made it possible for people to run up to 1 million cell experiments routinely.

FLERE HISTORIER FRA BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

India signs MoU with Pfizer to strengthen healthcare innovation ecosystem

In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, Government of India, has signed a Memorandum of Understanding (MoU) with US-based Pfizer Limited.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

New Zealand to lead new gene therapy trial for muscular dystrophy

The first clinical trial of a new treatment for a rare form of muscular dystrophy is being led by New Zealand-based University of Auckland's Centre for Brain Research.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Scientists in Australia grow living skin in world-first

Australia's University of Queensland (UQ) researchers have been the first in the world to successfully grow fully functioning human skin in a laboratory.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

India joins Health AI Global Regulatory Network to strengthen oversight of AI in healthcare

HealthAI - The Global Agency for Responsible AI in Health, has welcomed India as a pioneer country joining the HealthAI Global Regulatory Network (GRN), a global network of health regulators dedicated to the safe and effective use of artificial intelligence (AI) in healthcare.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

TVM Capital Healthcare announces first closing of $150 M Southeast Asia Fund

Singapore-based TVM Capital Healthcare, a global private equity investor and operator specialised in healthcare growth capital across emerging markets, has announced the first closing of its $150 million TVM Healthcare Southeast Asia Fund (SEA Fund).

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

National Yang Ming Chiao Tung University, TSH Biopharm collaborate to foster pharma talent in Taiwan

Taiwan's National Yang Ming Chiao Tung University (NYCU) and TSH Biopharm have signed a five-year industry-academia collaboration Memorandum of Understanding (MOU).

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Fujifilm Biosciences introduces BalanCD HEK293 Perfusion A Medium

Fujifilm Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the life science market, has announced the commercial launch of BalanCD HEK293 Perfusion A.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Korea makes smart patch that can run tests using sweat instead of blood

A research team at Korea Advanced Institute of Science and Technology has developed a smart patch that can precisely observe internal changes through sweat when simply attached to the body.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

ADB approves $106.9 M to strengthen secondary healthcare services in Sri Lanka

The Asian Development Bank (ADB) has approved a $106.9 million financing package to strengthen Sri Lanka's secondary curative care services, improve communicable disease prevention and control, and enhance the healthcare sector's governance and management capacity.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Epigenic Therapeutics raises $60 M to accelerate clinical development of medicines

China-based startup Epigenic Therapeutics, a clinical-stage innovative drug development company, has announced the completion of a $60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming Venture Partners and OrbiMed, and addition of new investors including IFSC and a renowned investment firm in the industry.

time to read

1 min

BioSpectrum Asia Oct 2025

Translate

Share

-
+

Change font size